ArticleRespiratory research2026
Single-cell N4-acetylcytidine regulatory landscape identifies ARIH1 as a ferroptosis-suppressive oncogenic driver in lung adenocarcinoma.
Article in Respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundN4-acetylcytidine (ac4C) is an emerging post-transcriptional RNA modification implicated in cancer biology, yet its cellular distribution, prognostic value, and functional relevance in lung adenocarcinoma (LUAD) remain insufficiently characterized. This study aimed to systematically define the ac4C-related regulatory landscape in LUAD and identify functionally and clinically relevant targets.
methodsA single-cell RNA-sequencing dataset comprising 87,634 cells was reanalyzed to quantify ac4C-related gene (acRG) activity across major cellular compartments using AUCell scoring. Prognostic acRGs were identified through differential expression analysis and univariate Cox regression, followed by integrative machine-learning modeling using LASSO and random survival forest algorithms. The biological function of ARIH1 was examined through cell proliferation assays, ferroptosis-related biochemical measurements, and mechanistic analyses including cycloheximide chase, co-immunoprecipitation, and ubiquitination assays.
resultsEpithelial cells displayed the highest acRG activity within the LUAD tumor ecosystem. A prognostic acRG-based signature was established, identifying ARIH1 as a high-risk factor associated with unfavorable survival outcomes. ARIH1 knockdown significantly inhibited LUAD cell growth and tumorigenic potential. Mechanistically, ARIH1 interacted with NCOA4 and promoted its K48-linked ubiquitination and proteasomal degradation, thereby suppressing ferritinophagy and ferroptosis. ARIH1 loss resulted in iron accumulation, lipid peroxidation, glutathione depletion, and ferroptotic cell death. Additionally, ARIH1 depletion markedly enhanced cisplatin-induced ferroptosis.
conclusionsThese findings map the single-cell ac4C regulatory architecture of LUAD and identify ARIH1 as a ferroptosis-suppressive E3 ubiquitin ligase, highlighting a potential therapeutic target to enhance ferroptosis-based and chemotherapy-based interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.